These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29454338)

  • 1. "Factors associated with non-small cell lung cancer treatment costs in a Brazilian public hospital".
    de Barros Reis C; Knust RE; de Aguiar Pereira CC; Portela MC
    BMC Health Serv Res; 2018 Feb; 18(1):124. PubMed ID: 29454338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated costs of advanced lung cancer care in a public reference hospital.
    Knust RE; Portela MC; Pereira CCA; Fortes GB
    Rev Saude Publica; 2017 Aug; 51():53. PubMed ID: 28832754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the direct costs of ischemic heart disease: evidence from a teaching hospital in BRAZIL, a retrospective cohort study.
    Schlatter RP; Hirakata VN; Polanczyk CA
    BMC Cardiovasc Disord; 2017 Jul; 17(1):180. PubMed ID: 28676042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain).
    Corral J; Espinàs JA; Cots F; Pareja L; Solà J; Font R; Borràs JM
    BMC Health Serv Res; 2015 Feb; 15():70. PubMed ID: 25889153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer.
    Maslove L; Gower N; Spiro S; Rudd R; Stephens R; West P
    Thorax; 2005 Jul; 60(7):564-9. PubMed ID: 15994264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.
    Zhang X; Beachler DC; Masters E; Liu F; Yang M; Dinh J; Jamal-Allial A; Kolitsopoulos F; Lamy FX
    J Manag Care Spec Pharm; 2022 Feb; 28(2):255-265. PubMed ID: 34854733
    [No Abstract]   [Full Text] [Related]  

  • 8. Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands.
    Pompen M; Gok M; Novák A; van Wuijtswinkel R; Biesma B; Schramel F; Stigt J; Smit H; Postmus P
    Lung Cancer; 2009 Apr; 64(1):110-6. PubMed ID: 18805601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct costs for outpatient excess body weight treatment in Brazilian children and adolescents attending a public children's hospital.
    Hanauer AD; Corrêa ZGD; Blazius G; Prates RC; Mastroeni MF
    J Pediatr (Rio J); 2024; 100(4):444-454. PubMed ID: 38608721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel.
    Isla D; González-Rojas N; Nieves D; Brosa M; Finnern HW
    Clin Transl Oncol; 2011 Jul; 13(7):460-71. PubMed ID: 21775273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study.
    Skinner KE; Fernandes AW; Walker MS; Pavilack M; VanderWalde A
    J Med Econ; 2018 Feb; 21(2):192-200. PubMed ID: 29041833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
    Pimentel FL; Bhalla S; Laranjeira L; Guerreiro M
    Lung Cancer; 2006 Jun; 52(3):365-71. PubMed ID: 16650499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a method to determine the cost of breast cancer treatment with chemotherapy at Groote Schuur Hospital, Cape Town, South Africa.
    Guzha NT; Thebe T; Butler N; Valodia PN
    S Afr Med J; 2020 Mar; 110(4):296-301. PubMed ID: 32657741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
    Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
    J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients.
    Thronicke A; Reinhold T; von Trott P; Grah C; Matthes B; Matthes H; Schad F
    PLoS One; 2020; 15(7):e0236426. PubMed ID: 32716969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost analysis of hospital treatment--two chemotherapic regimens for non-surgical non-small cell lung cancer. GFPC (Groupe Français Pneumo Cancérologie).
    Vergnenègre A; Perol M; Pham E
    Lung Cancer; 1996 Feb; 14(1):31-44. PubMed ID: 8696719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care--an observational analysis on non-small-cell lung cancer patients.
    Ihbe-Heffinger A; Paessens B; Berger K; Shlaen M; Bernard R; von Schilling C; Peschel C
    Support Care Cancer; 2013 Jun; 21(6):1665-75. PubMed ID: 23338228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan.
    Ramsey SD; Clarke L; Kamath TV; Lubeck D
    J Manag Care Pharm; 2006; 12(6):472-8. PubMed ID: 16925455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs of vaginal delivery and Caesarean section at a tertiary level public hospital in Islamabad, Pakistan.
    Khan A; Zaman S
    BMC Pregnancy Childbirth; 2010 Jan; 10():2. PubMed ID: 20085662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs of care associated with non-small-cell lung cancer in a commercially insured cohort.
    Hillner BE; McDonald MK; Desch CE; Smith TJ; Penberthy LT; Maddox P; Retchin SM
    J Clin Oncol; 1998 Apr; 16(4):1420-4. PubMed ID: 9552046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.